Unituxin — Gross Profit
United Therapeutics Unituxin — Gross Profit decreased by 13.8% to $48.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.3%, from $53.00M to $48.60M. Over 4 years (FY 2021 to FY 2025), Unituxin — Gross Profit shows an upward trend with a 2.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher gross profit indicates strong pricing power or efficient production, while declining profit suggests rising input costs or pricing pressure.
Detailed definition
This metric represents the profit a specific product line generates after deducting the direct costs of production from...
Peer comparison
Comparable to 'Segment Gross Profit' or 'Product Gross Margin' reported by peer pharmaceutical companies.
uthr_segment_unituxin_gross_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.10M | $52.90M | $46.80M | $52.30M | $41.00M | $43.40M | $33.10M | $44.40M | $41.60M | $47.20M | $49.20M | $54.80M | $47.90M | $56.30M | $65.30M | $53.00M | $55.60M | $44.30M | $56.40M | $48.60M |
| QoQ Change | — | +10.0% | -11.5% | +11.8% | -21.6% | +5.9% | -23.7% | +34.1% | -6.3% | +13.5% | +4.2% | +11.4% | -12.6% | +17.5% | +16.0% | -18.8% | +4.9% | -20.3% | +27.3% | -13.8% |
| YoY Change | — | — | — | — | -14.8% | -18.0% | -29.3% | -15.1% | +1.5% | +8.8% | +48.6% | +23.4% | +15.1% | +19.3% | +32.7% | -3.3% | +16.1% | -21.3% | -13.6% | -8.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's unituxin — gross profit?
- United Therapeutics (UTHR) reported unituxin — gross profit of $48.60M in Q1 2026.
- How has United Therapeutics's unituxin — gross profit changed year-over-year?
- United Therapeutics's unituxin — gross profit decreased by 8.3% year-over-year, from $53.00M to $48.60M.
- What is the long-term trend for United Therapeutics's unituxin — gross profit?
- Over 4 years (2021 to 2025), United Therapeutics's unituxin — gross profit has grown at a 2.7% compound annual growth rate (CAGR), from $188.10M to $209.30M.
- What does unituxin — gross profit mean?
- The revenue from a product minus the direct costs to produce it.